Article Per Year (5 Year)
p-Index From 2020 - 2025
0.23
P-Index
This Author published in this journals
All Journal MPSJ
Ishak, Andi Khuswatun Khazanah
Unknown Affiliation
Medicine & Pharmacology

Published : 1 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search

 1 
LITERATURE REVIEW : Uji Molekular Docking Senyawa Osimertinib Beserta Turunannya Terhadap Reseptor Tirosin kinase Pada kanker Paru- Paru Yuliana, Dewi; Aminah, Aminah; Ishak, Andi Khuswatun Khazanah
Makassar Pharmaceutical Science Journal (MPSJ) Vol 2 No 1 (2024)
Publisher : PHARMACY UMI JOURNAL SYSTEM

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33096/mpsj.v2i1.134

Abstract

Lung cancer is all malignancy in the lung, including malignancy originating from the lung itself (primary). In clinical terms, what is meant by primary lung cancer is a malignant tumor originating from the bronchial epithelium. Current anti-lung cancer therapy has the goal of inhibiting the activity of EGFR. One of the substances that inhibits the action of EGFR is Tyrosine Kinase Inhibitor (TKI). Osimertinib has the potential to inhibit the phosphorylation of cells containing EGFR mutations. This review article aims to determine the ability of osimertinib compounds and their derivatives as lung cancer therapeutic agents against tyrosine kinase receptors using the molecular docking method. The research method used is literature review using two databases, namely Pubmed and Google Scholar for the last 10 years from 2013-2023. And the results obtained are that Osimertinib can be used as a lung cancer therapeutic agent against tyrosine kinase receptors
Co-Authors Aminah Aminah Dewi Yuliana